Skip to content

Study · Non-randomized trial · 2016

2 results

[Clinical and neurophysiological heterogeneity of attention deficit hyperactivity disorder].

Chutko LS, Yakovenko EA, Surushkina SY, Anisimova TI, Kropotov YD

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2016Cited by 3 (Europe PMC)

PMID27845323 (opens in a new tab)DOI10.17116/jnevro2016116101117-121 (opens in a new tab)PepBankPUB-27845323
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with idiopathic ADHD, Cerebrolysin treatment was associated with clinical improvement in 70.0% of patients.

    In plain wordsIn children with idiopathic ADHD, Cerebrolysin treatment was associated with improvement in 70.0% of patients.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseClinical improvement in idiopathic ADHD
    Study

    n: not reported in source

    Outcome group
    Psychiatric symptoms · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Clinical improvement
    70%
    Idiopathic ADHD

    Source sentences

    Summary
    The high clinical efficacy (improvement in 70.0% of patients with idiopathic form of ADHD and 86.7% of patients with residual-organic form of the disease) was found.
    2 context sentences
    Summary · context
    To determine clinical/neurophysiological characteristics of different forms of attention deficit hyperactivity disorder (ADHD) and the efficacy of treatment with cerebrolysin.
    Summary · context
    Sixty children, aged 9 to 12 years, with ADHD were examined using clinical and electroencephalographic methods.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with residual-organic ADHD, Cerebrolysin treatment was associated with clinical improvement in 86.7% of patients.

    In plain wordsIn children with residual-organic ADHD, Cerebrolysin treatment was associated with improvement in 86.7% of patients.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseClinical improvement in residual-organic ADHD
    Study

    n: not reported in source

    Outcome group
    Psychiatric symptoms · Nervous system and cognition
    Studied dose
    Dose not stated

    Measurements

    Clinical improvement
    86.7%
    Residual-organic ADHD

    Source sentences

    Summary
    The high clinical efficacy (improvement in 70.0% of patients with idiopathic form of ADHD and 86.7% of patients with residual-organic form of the disease) was found.
    2 context sentences
    Summary · context
    To determine clinical/neurophysiological characteristics of different forms of attention deficit hyperactivity disorder (ADHD) and the efficacy of treatment with cerebrolysin.
    Summary · context
    Sixty children, aged 9 to 12 years, with ADHD were examined using clinical and electroencephalographic methods.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.